EP Patent

EP4008315A1 — A process for formulations of dapagliflozin and metformin hydrochloride

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2022-06-08 · 4y expired

What this patent protects

The present invention relates to a process for the preparation of a film coated tablet formulation comprising dapagliflozin and metformin hydrochloride. The process is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the d…

USPTO Abstract

The present invention relates to a process for the preparation of a film coated tablet formulation comprising dapagliflozin and metformin hydrochloride. The process is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the disadvantages of both active ingredients.

Drugs covered by this patent

Patent Metadata

Patent number
EP4008315A1
Jurisdiction
EP
Classification
Expires
2022-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.